PAVmed (PAVmed) Debt-to-Equity

: -0.91 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

PAVmed's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $45.77 Mil. PAVmed's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.96 Mil. PAVmed's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-53.83 Mil. PAVmed's debt to equity for the quarter that ended in Dec. 2023 was -0.91.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for PAVmed's Debt-to-Equity or its related term are showing as below:

PAVM' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.78 Med: -1.52 Max: 7.89
Current: -0.91

During the past 10 years, the highest Debt-to-Equity Ratio of PAVmed was 7.89. The lowest was -3.78. And the median was -1.52.

PAVM's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.2 vs PAVM: -0.91

PAVmed Debt-to-Equity Historical Data

The historical data trend for PAVmed's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PAVmed Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-2.13

7.89

-3.78

-0.91

PAVmed Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																-3.78	-2.24	-1.53	-1.15	-0.91

Competitive Comparison

For the Medical Devices subindustry, PAVmed's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PAVmed Debt-to-Equity Distribution

For the Medical Devices & Instruments industry and Healthcare sector, PAVmed's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where PAVmed's Debt-to-Equity falls into.

PAVmed Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

PAVmed's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(45.765	+	2.96)	/	-53.831
	=	-0.91

PAVmed's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(45.765	+	2.96)	/	-53.831
	=	-0.91

PAVmed (NAS:PAVM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

PAVmed Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of PAVmed's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

PAVmed (PAVmed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PAVmed Inc (NAS:PAVM) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

360 Madison Avenue, 25th Floor, New York, NY, USA, 10017

Website

http://www.pavmed.com

PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard and the Veris Cancer Care Platform.

Executives

Michael J Glennon	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Michael Adam Gordon	officer: General Counsel	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Shaun O'neil	officer: Chief Operating Officer	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
James L Cox	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Debra White	director	C/O PAVMED INC., ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Ronald M Sparks	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Brian J. Deguzman	officer: Chief Medical Officer	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Dennis M Mcgrath	officer: President & CFO	C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Lishan Aklog	director, 10 percent owner, officer: Chairman and CEO	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Joan B Harvey	director	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Timothy E Baxter	director	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Matthew Sirovich	10 percent owner	C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123
Ira Scott Greenspan	director	888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106
David S. Battleman	director	C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
Joshua R Lamstein	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170